Lilly cancer drug pipeline hit by trial setback

Lilly cancer drug pipeline hit by trial setback

Source: 
Biopharma Dive
snippet: 

Pegilodeckin, an immunotherapy acquired in the company's $1.6 billion deal for Armo BioSciences, failed to extend survival in patients with pancreatic cancer.